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ABSTRACT
Objectives: This double-blind trial evaluated the
efficacy and safety of abatacept or infliximab
vs placebo. The primary objective of this study was to
evaluate the mean change from baseline in Disease
Activity Score (based on erythrocyte sedimentation
rates; DAS28 (ESR)) for the abatacept vs placebo groups
at day 197.
Methods: Patients with rheumatoid arthritis (RA) and an
inadequate response to methotrexate (MTX) were
randomised 3:3:2 to abatacept (,10 mg/kg every
4 weeks, n=156), infliximab (3 mg/kg every 8 weeks,
n=165), or placebo (every 4 weeks, n=110) and
background MTX. Safety and efficacy were assessed
throughout the study.
Results: Similar patient demographics and
clinical characteristics were present at baseline
between groups, with mean scores of ,1.7 for HAQ-DI
and 6.8 for DAS28 (ESR). At 6 months, mean
changes in DAS28 (ESR) were significantly greater for
abatacept vs placebo (–2.53 vs –1.48, p,0.001) and
infliximab vs placebo (–2.25 vs –1.48, p,0.001). For
abatacept vs infliximab treatment at day 365, reductions
in the DAS28 (ESR) were –2.88 vs –2.25. At day 365,
the following response rates were observed for
abatacept and infliximab, respectively: American
College of Rheumatology (ACR) 20, 72.4 and 55.8%;
ACR 50, 45.5 and 36.4%; ACR 70, 26.3 and 20.6%;
low disease activity score (LDAS), 35.3 and 22.4%;
DAS28-defined remission, 18.7 and 12.2%; good
European League Against Rheumatism (EULAR)
responses, 32.0 and 18.5%; and Health Assessment
Questionnaire Disability Index (HAQ-DI), 57.7 and 52.7%.
Mean changes in physical component summary (PCS)
were 9.5 and 7.6, and mental component summary
(MCS) were 6.0 and 4.0, for abatacept and infliximab,
respectively. Over 1 year, adverse events (AEs) (89.1 vs
93.3%), serious AEs (SAEs) (9.6 vs 18.2%), serious
infections (1.9 vs 8.5%) and discontinuations due to AEs
(3.2 vs 7.3%) and SAEs (2.6 vs 3.6%) were lower with
abatacept than infliximab.
Conclusions: In this study, abatacept and
infliximab (3 mg/kg every 8 weeks) demonstrated
similar efficacy. Overall, abatacept had a relatively
more acceptable safety and tolerability profile,
with fewer SAEs, serious infections, acute infusional
events and discontinuations due to AEs than the
infliximab group.
Trial registration number: NCT00095147.
Abatacept is a selective T-cell co-stimulation
modulator, that modulates the CD80/
CD86:CD28 co-stimulatory signal required for full
T-cell activation.
1 The mechanism of action of
abatacept is fundamentally different to that of
other biological disease-modifying antirheumatic
drugs (DMARDs) for the treatment of rheumatoid
arthritis (RA). The efficacy of abatacept has
previously been demonstrated in patients with
RA and an inadequate response to methotrexate
(MTX)
2 and anti-tumour necrosis factor (TNF)
agents,
3 respectively.
The ATTEST (for ‘‘Abatacept or infliximab vs
placebo, a Trial for Tolerability, Efficacy and Safety
in Treating rheumatoid arthritis’’) trial was
designed to obtain data on the magnitude of the
treatment effect in RA of abatacept or infliximab
(an established inhibitor of TNF for RA) vs
placebo, and to obtain relative efficacy and safety
data on these two biological treatments in a single
study. The study utilised a double-blind, rando-
mised, placebo-controlled design for the first
6 months to validate efficacy responses, and the
study duration allowed for the opportunity to
directly compare the safety profile of the active
biologic treatment groups over 1 year.
METHODS
Patients
Eligible patients met the American College of
Rheumatology (ACR) criteria for RA, were at least
18 years of age, had RA for at least 1 year,
4 and had
an inadequate response to MTX, as demonstrated
by ongoing active disease (at randomisation >10
swollen joints, >12 tender joints, and C-reactive
protein (CRP) levels >1 mg/dl using a high
sensitivity assay (upper limit of the normal range,
0.5)). All patients had received MTX >15 mg/week
for >3 months prior to randomisation (stable for
at least 28 days) and washed out all DMARDs
(>28 days prior) except for MTX. No prior
experience of abatacept or anti-TNF therapy was
permitted. All patients were screened for tubercu-
losis (TB) by purified protein derivative (PPD)
testing and chest x ray. The protocol used for TB
screening was the same as that employed in the
‘‘Anti-TNF Trial in rheumatoid arthritis with
Concomitant Therapy’’ (ATTRACT) trial.
5
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197: oral corticosteroids ((10 mg of prednisone or equivalent
daily (stable for >25 out of 28 days prior to randomisation)),
and/or stable non-steroidal anti-inflammatory drugs (NSAIDs)
including acetyl salicylic acid, and analgesics not containing
aspirin or NSAIDs. No MTX dose adjustments were permitted
except in the occurrence of adverse events (AEs). Between days
198–365, dose modification was permitted for MTX ((25 mg
weekly) and oral corticosteroids ((10 mg prednisone or
equivalent daily); hydroxychloroquine, sulfasalazine, gold, or
azathioprine were also permitted. Premedication prior to
infusions of study drug was left at the discretion of the
investigator (not required by protocol).
Study design
ATTEST was a randomised, double-blind, double-dummy,
placebo- and active (infliximab)-controlled, 12-month global
trial. Adult patients with active RA and an inadequate response
to MTX were randomised by centre in a 3:3:2 ratio to 6 months
of abatacept (approximating 10 mg/kg), infliximab (3 mg/kg),
or placebo treatment by intravenous (IV) infusion, on a
background of MTX. Assessors, physicians and patients were
blinded to the treatment group assignment for 1 year.
The study was approved by the institutional review boards
and independent ethics committees at participating sites, and
was carried out in accordance with the ethical principles of the
Declaration of Helsinki. All patients provided written informed
consent before randomisation.
Treatment with placebo was limited to days 1–197 to provide
internal validity to the trial design and the clinical response
rates of the two active treatment groups. On day 198, placebo-
treated patients were reallocated to abatacept (with blinding
maintained). Patients initially randomised to abatacept or
infliximab continued their treatment. Clinical efficacy and
safety assessments are presented for the abatacept, placebo and
infliximab groups up to day 197, and for the abatacept and
infliximab groups up to day 365 (excluding patients in the
placebo group who were reallocated to abatacept at day 198).
Study drugs
Abatacept was dosed according to weight: patients weighing
less than 60 kg, 60–100 kg, or more than 100 kg received
500 mg, 750 mg, or 1000 mg of abatacept, respectively.
Infliximab was dosed at 3 mg/kg for all patients. Abatacept
was administered by IV infusion on days 1, 15 and 29, and every
28 days thereafter, up to and including day 337 (with normal
saline received on day 43). Infliximab was administered on days
1, 15, 43 and 85, and every 56 days thereafter (normal saline was
received at the remaining visit days). Two IV bags were infused
simultaneously to ensure blinding to treatment group assign-
ment, one over 30 min (abatacept or placebo) and one over 2 h
(infliximab or placebo).
Objectives
The primary endpoint was to evaluate a reduction in disease
activity, measured by Disease Activity Score 28 (based on
erythrocyte sedimentation rate levels; DAS28 (ESR)) with
abatacept vs placebo at 6 months. Secondary endpoints
included mean reduction in DAS28 (ESR) with infliximab vs
placebo at 6 months. Additional secondary endpoints at
6 months and 1 year included: mean reduction in DAS28
(ESR) with abatacept vs infliximab; DAS28 (ESR) European
League Against Rheumatism (EULAR) responses;
6 low disease
activity score (LDAS; DAS28 (ESR) (3.2); DAS28
(ESR)-defined remission (DAS28 (ESR) ,2.6); ACR 20, 50 and
70 responses;
7 Health Assessment Questionnaire Disability
Index (HAQ-DI) response rates (>0.3 improvement from
baseline); and mean changes in the physical and mental
component summary (PCS and MCS, respectively) scores, and
eight subscales of the Short Form-36 (SF-36). Tertiary endpoints
included comparative safety at 1 year between the abatacept
and infliximab groups.
Clinical assessments
Disease activity was assessed using the validated DAS28 (ESR).
8
The EULAR criteria were used to assess good responses (endpoint
DAS28 (ESR) of (3.2 and an improvement from baseline of
>1.2).
6 Signs and symptoms of RA were evaluated using ACR 20,
50 and 70 response rates based on the ACR criteria.
7
Physical function was assessed using the HAQ-DI.
9 Health-
related quality of life (HRQoL) was assessed using the SF-36.
10
Safety
All patients who received at least one dose of study drug were
evaluated for safety, including all reported AEs, serious AEs
(SAEs), and clinically significant changes in vital signs, physical
exams, and clinical laboratory test abnormalities.
Sample size calculation
The sample size and power were calculated to detect a
treatment difference in the primary analysis of a mean change
from baseline in DAS28 (ESR) for the abatacept vs placebo
groups at day 197. Prospectively, this study was not powered
with a superiority or non-inferiority design to compare the two
active arms.
Statistical analyses
All patients who received at least one dose of study medication
were assessed for efficacy and safety (intent-to-treat popula-
tion). At day 197, the abatacept or infliximab groups were
compared with the placebo group by analyses of covariance
(ANCOVA) for mean changes from baseline in DAS28 (ESR)
and in the SF-36 (PCS and MCS). The model included the
change as the dependent variable, with treatment group as a
main effect and the baseline score as an additional covariate.
The proportion of patients with ACR 20, 50 and 70 responses,
LDAS, DAS28-defined remission, a good EULAR response and a
clinical meaningful HAQ-DI response was calculated. The x
2
test was performed to evaluate the differences (and 95% CIs)
between the abatacept or infliximab groups and placebo. At day
365, the reference group was changed to infliximab.
Patients who discontinued the study prematurely were
considered as non-responders subsequent to the time of
discontinuation for ACR 20, 50 and 70 responses, good
EULAR responses and clinically meaningful HAQ-DI responses.
For all continuous measurements (mean changes in DAS28, SF-
36 and the HAQ-DI score), LDAS and DAS28-defined remission
the last observations prior to the discontinuation were carried
forward (LOCF). To access the effect of antirheumatic medica-
tions on the abatacept and infliximab treatment groups, a
predefined sensitivity analysis was conducted on the data with
the last DAS28 (ESR) score just prior to the initiation of the
additional DMARD, or any increase in MTX or corticosteroid
use during treatment days 198–365 carried forward.
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tabulated by treatment group at days 197 and 365.
RESULTS
Baseline demographics and clinical characteristics
A total of 431 patients were randomised and treated with
abatacept (n=156), placebo (n=110) or infliximab (n=165)
(fig 1). Baseline demographics and clinical characteristics were
similar between groups (table 1). At randomisation, patients
had active disease despite background MTX (mean DAS28
(ESR) of 6.8–6.9, tender joint counts 30.3–31.7, swollen joint
counts 20.1–21.3 and mean HAQ-DI of 1.7–1.8). The mean dose
of MTX was 16.3–16.6 mg and mean treatment duration was
18.3–23.7 months.
Use of additional medications
Concomitant medications and NSAIDs were used by a similar
proportion of patients across treatment groups at randomisa-
tion (table 1). Between days 198–365, when the protocol
permitted adjustments to background medications, 12.8% and
17.6% of abatacept and infliximab-treated patients, respectively,
added a DMARD, or increased their dose of MTX/corticoster-
oids from baseline.
Figure 1 Patient disposition over 1
year. The ATTEST trial was a 12-month
global trial conducted at 86 sites in the
US (20 sites), Europe (18 sites (5 in
Poland, 4 in Spain, 4 in Sweden, 2 in
Russia, 2 in Denmark and 1 in
Switzerland)), Canada (11 sites), Australia
(6 sites), Mexico (10 sites), Argentina (5
sites), Brazil (8 sites), Peru (5 sites) and
South Africa (3 sites). Patients were
randomised in a 3:3:2 ratio to 6 months
of abatacept (approximating 10 mg/kg),
infliximab (3 mg/kg), or placebo
treatment. During days 198–365, efficacy
and safety data are not presented for the
placebo group following reallocation to
abatacept.
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During the first 6 months, discontinuations occurred in 5.8, 2.7
and 7.9% of the abatacept, placebo and infliximab groups,
respectively. Between days 198–365, 5.1 and 6.7%, of the
abatacept and infliximab groups, respectively, discontinued.
Discontinuation due to AEs and SAEs were highest in the
infliximab group in both periods (fig 1). Similar numbers of
patients from the abatacept and infliximab groups completed 1
year of treatment (fig 1).
Clinical efficacy
DAS28
At day 197, the reduction in DAS28 (ESR), was significantly
greater with abatacept vs placebo (–2.53 vs –1.48, p,0.001;
fig 2A). A greater proportion of patients also experienced a good
EULAR response (20.0 vs 10.8%), LDAS (20.7 vs 10.8%) and
were in DAS28 (ESR)-defined remission (11.3 vs 2.9%), for
abatacept vs placebo, respectively (fig 2B). Reductions in DAS28
(ESR) were also significantly greater in the infliximab vs placebo
groups at day 197 (–2.25 vs –1.48, p,0.001; fig 2A), with a
higher proportion of patients experiencing a good EULAR
response (22.9 vs 10.8%), LDAS (25.6 vs 10.8%) and were in
DAS28 (ESR)-defined remission (12.8 vs 2.9%), respectively
(fig 2B). At day 197, the relative efficacy of abatacept and
infliximab as assessed by the DAS28 (ESR) was similar.
At day 365, a greater reduction in DAS28 (ESR) was observed
with abatacept than with infliximab (fig 2A; –2.88 vs –2.25;
estimate of difference (95% CI)=–0.62 (–0.96, –0.29)). Also, the
proportion of patients achieving a good EULAR response (32.0
vs 18.5%, estimate of difference (95% CI)=13.5% (3.6, 23.3)),
LDAS (35.3 vs 22.4%, estimate of difference (95% CI)=12.9
(2.1, 23.7)), and DAS28 (ESR)-defined remission (18.7 vs 12.2%,
estimate of difference (95% CI)=18.7 (–2.2, 15.2)) were higher
with abatacept compared with infliximab (fig 2B).
When disease activity was assessed using a sensitivity analysis
(LOCF prior to increase in antirheumatic medications was
performed), consistent improvements were demonstrated with
abatacept: DAS28 (ESR) mean changes were significantly
greater with abatacept vs infliximab at day 365 (–2.8 vs –2.2,
respectively (difference from infliximab of –0.7, 95% CI of –1.0,
–0.3)).
American College of Rheumatology response rates
At day 197, ACR 20, 50 and 70 responses were significantly
greater with abatacept vs placebo (ACR 20: 66.7 vs 41.8%,
p,0.001; ACR 50: 40.4 vs 20.0%, p,0.001; and ACR 70: 20.5 vs
9.1%, p=0.019). ACR 20, 50 and 70 responses were also
significantly higher in the infliximab group vs placebo (ACR 20:
59.4 vs 41.8%, p=0.006; ACR 50: 37.0 vs 20.0%, p=0.004; and
ACR 70: 24.2 vs 9.1%, p=0.002). The onset of response, as
assessed by ACR 20 response rates, was generally more rapid for
infliximab compared with abatacept (fig 3), however, by day 85,
responses were similar (fig 3). Abatacept and infliximab
demonstrated similar responses at day 197. During the second
6 months of the trial, the responses associated with abatacept
were maintained, while those observed with infliximab were
not. At day 365, ACR 20 responses were higher with abatacept
than with infliximab (ACR 20: 72.4 vs 55.8%, difference of 16.7,
95% CI=5.5, 27.8). In addition, the percentages of ACR 50 and
70 responders were numerically higher with abatacept vs
infliximab treatment (with overlapping 95% CIs for the
estimate of difference for ACR 50: 45.5 vs 36.4%, estimate of
difference (95% CI)=9.1 (–2.2, 20.5); ACR 70: 26.3 vs 20.6%,
estimate of difference (95% CI)=5.7 (–4.2, 15.6), respectively).
Physical function
At 6 months, significantly more patients in the abatacept group
than in the placebo group demonstrated a clinically meaningful
Table 1 Baseline demographics and clinical characteristics
Demographic/characteristic
Abatacept + MTX
(n=156)
Placebo + MTX
(n=110)
Infliximab + MTX
(n=165)
Age, years (SD) 49.0 (12.5) 49.4 (11.5) 49.1 (12.0)
Gender, % female 83.3 87.3 82.4
Race, % Caucasian 80.8 76.4 80.6
Geographic origin:
North America, n (%) 16 (10.3) 10 (9.1) 15 (9.1)
South America, n (%) 93 (59.6) 66 (60.0) 96 (58.2)
Europe, n (%) 39 (25.0) 29 (26.4) 39 (23.6)
Rest of the world, n (%) 8 (5.1) 5 (4.5) 15 (9.1)
Disease duration, years (SD) 7.9 (8.5) 8.4 (8.6) 7.3 (6.2)
Tender joints, n (SD) 31.6 (13.9) 30.3 (11.7) 31.7 (14.5)
Swollen joints, n (SD) 21.3 (8.6) 20.1 (7.0) 20.3 (8.0)
Erythrocyte sedimentation rate, mm/h (SD) 49.4 (31.2) 47.0 (32.6) 47.8 (30.4)
C-reactive protein levels, mg/dl (SD) 3.1 (2.7) 2.7 (2.6) 3.3 (3.2)
DAS28 (ESR), n (SD) 6.9 (1.0) 6.8 (1.0) 6.8 (0.9)
HAQ-DI, 0–3 (SD) 1.8 (0.6) 1.8 (0.7) 1.7 (0.7)
Rheumatoid factor positive, n (%) 136 (87.2) 85 (77.3) 140 (84.8)
Concomitant medications
Total patients on concomitant medications, n (%) 156 (100) 110 (100) 165 (100)
MTX, n (%) 156 (100) 110 (100) 164 (99.4)
Dose, mg/week (SD) 16.5 (3.7) 16.6 (3.7) 16.3 (3.6)
Duration, months (SD) 18.3 (20.0) 23.7 (25.6) 23.6 (26.8)
Corticosteroids, n (%) 118 (75.6) 77 (70.0) 118 (71.5)
NSAIDs, n (%) 133 (85.3) 93 (84.5) 142 (86.1)
MTX, methotrexate; DAS28 (ESR), Disease Activity Score 28 (based on erythrocyte sedimentation rate levels); HAQ-DI, Health
Assessment Questionnaire Disability Index; NSAID, non-steroidal anti-inflammatory drug.
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40.9%, respectively, p=0.001). Similarly, significantly more
patients in the infliximab group vs the placebo group achieved a
HAQ-DI response (58.8 vs 40.9%, p=0.005). At day 365, HAQ-
DI responses were maintained in the abatacept and infliximab
groups (57.7 and 52.7%, respectively, estimate of difference
(95% CI)=5.0 (–6.5, 16.5)).
Health-related quality of life
Patients in the abatacept group experienced statistically
significantly greater improvements from baseline in the PCS
(p,0.001) and MCS (p=0.004) of the SF-36, and in each of the
eight individual subscales compared with placebo, following
6 months of treatment (fig 4A). Patients in the infliximab group
also experienced significantly greater improvements from base-
line in the PCS (p=0.002) and MCS (p=0.027), and all eight
subscales of the SF-36 at day 197 compared with patients in the
placebo group. At day 365, greater improvements from baseline
in the PCS were observed with abatacept vs infliximab
(difference of 1.93, 95% CI=0.02, 3.84). Improvements in the
MCS (difference of 1.92, 95% CI=–0.30, 4.15) and in all eight
subscales were also numerically higher with abatacept vs
infliximab (fig 4B).
Safety
A summary of safety for all patients who received at least one
dose of study medication is presented in table 2 (excluding the
original placebo group between days 197–365).
Summary of safety for days 1–197
During days 1–197, AEs were reported by a similar proportion of
patients in the abatacept (82.7%), placebo (83.6%) and
infliximab (84.8%) groups. Two deaths were reported: one
patient in the abatacept group due to a cerebrovascular accident,
and one patient in the infliximab group due to fibrosarcoma.
Overall, the frequency of AEs, related AEs and discontinuations
due to AEs or SAEs was similar for the abatacept and placebo
Figure 2 Disease Activity Score 28 (DAS28) based on erythrocyte
sedimentation rates (ESR). A. DAS28 (ESR) mean changes from baseline
at days 197 and 365. Error bars represent standard error of the mean. B.
European League Against Rheumatism (EULAR) good responses, low
DAS (LDAS; DAS28 (3.2) and DAS28 (ESR)-defined remission at day
197 and at day 365. Data are presented for the intent-to-treat population
with a last-observation carried forward analysis for mean changes in
DAS28 (ESR), LDAS and DAS28 (ESR)-defined remission. Good EULAR
responses were presented for the intent-to-treat population with patients
who discontinued the study prematurely considered as non-responders
subsequent to the time of discontinuation. Error bars show standard error
of the mean. *Adjustment based on covariance with treatment as factor
and baseline as covariant.
Figure 3 American College of Rheumatology (ACR) responses over 1
year. Proportion of patients with ACR 20, 50 and 70 responses was
assessed on each visit day. Data are presented for the intent-to-treat
population with a last-observation carried forward analysis. *Infliximab
was administered on days 1, 15, 43, 85 and then every 56 days
thereafter. Abatacept dosing occured at each visit day presentation
following the assesment of efficacy.
Extended report
1100 Ann Rheum Dis 2008;67:1096–1103. doi:10.1136/ard.2007.080002groups. Between days 1–197, SAEs were lower with abatacept
vs placebo (5.1 vs 11.8%), the difference was largely attributed
to a higher frequency of gastrointestinal disorders, bacterial
infections and musculoskeletal disorders in the placebo group.
For the infliximab vs placebo groups during the same period, the
frequency of AEs (84.8 vs 83.6%), related AEs (44.8 vs 41.8%)
and SAEs (11.5 vs 11.8%) were similar; however, a higher
proportion of patients in the infliximab group compared with
the placebo group reported related SAEs (4.8 vs 2.7%),
discontinued due to AEs (4.8 vs 0.9%), and discontinued due
to SAEs (2.4 vs 0%). The higher frequency of SAEs in the
infliximab vs placebo groups was largely due to an increase in
serious infections (4.2 vs 2.7%, respectively).
The most frequently reported AEs were primarily infections
and infestations, and most were of mild to moderate intensity.
Acute infusional AEs (within 3 h of the start of dosing) were
reported in 5.1, 10.0 and 18.2% of the abatacept, placebo and
infliximab groups, respectively (table 3). Infections and infesta-
tions were reported in 48.1, 51.8 and 52.1% of the abatacept,
placebo and infliximab groups, respectively.
Serious infections were lower in the abatacept group (1.3%)
than in the placebo (2.7%) and infliximab (4.2%) groups at day
197 (table 4), with patients originating from Latin America
(abatacept, 8.3%; placebo, 16.7%; infliximab, 25.0%) and Europe
(abatacept, 8.3%; placebo, 8.3%; infliximab, 33.3%). Between
days 1–197, two opportunistic infections occurred (a pseudo-
monal lung infection and a Pneumocysitis jiroveci pneumonia) in
the infliximab group.
Autoimmune symptoms or disorders were uncommon
(,1%), occurring at a similar frequency across groups (table 2).
Malignancies were reported for four patients, including one
abatacept-treated patient (bladder cancer), one placebo-treated
patient (non-melanomatous skin cancer) and two infliximab-
treated patients (malignant anorectal neoplasm and fibrosar-
coma in one patient for each).
Summary of safety for days 1–365 for abatacept and infliximab
groups
During the entire 12-month, double-blind period (days 1–365),
SAEs, related SAEs, and discontinuations due to SAEs were
lower with abatacept than infliximab (SAEs: 9.6 vs 18.2%;
related SAEs: 3.2 vs 8.5%; and discontinuations due to SAEs: 2.6
vs 3.6%, respectively (table 2)). Overall, AEs, related AEs and
discontinuations due to AEs were also lower with abatacept
than with infliximab (AEs: 89.1 vs 93.3%; related AEs: 46.2 vs
58.2%: and discontinuations due to AEs: 3.2 vs 7.3%,
respectively). An additional infliximab-treated patient with
Figure 4 Health-related quality of life. A. Mean change in physical and
mental component summary (PCS and MCS, respectively) scores and
the individual subscales of the Short Form-36 (SF-36) from day 1 to day
197. B. Mean change in PCS and MCS scores and the individual
subscales of the SF-36 from day 1 to day 365; Data are presented for the
intent-to-to treat population with a last observation carried forward
analysis.
Table 2 Summary of safety to day 197 and day 365
Days 1–197 Days 1–365
Abatacept + MTX
(n=156)
Placebo + MTX
(n=110)
Infliximab + MTX
(n=165)
Abatacept + MTX
(n=156)
Infliximab + MTX
(n=165)
n (%)* n (%)* n (%)* n (%)* n (%)*
Deaths 1 (0.6) 0 1 (0.6) 1 (0.6) 2 (1.2)
SAEs 8 (5.1) 13 (11.8) 19 (11.5) 15 (9.6) 30 (18.2)
Related SAEs 3 (1.9) 3 (2.7) 8 (4.8) 5 (3.2) 14 (8.5)
Discontinuations due to SAEs 2 (1.3) 0 4 (2.4) 4 (2.6) 6 (3.6)
AEs 129 (82.7) 92 (83.6) 140 (84.8) 139 (89.1) 154 (93.3)
Related AEs 64 (41.0) 46 (41.8) 74 (44.8) 72 (46.2) 96 (58.2)
Discontinuations due to AEs 3 (1.9) 1 (0.9) 8 (4.8) 5 (3.2) 12 (7.3)
Serious infections 2 (1.3) 3 (2.7) 7 (4.2) 3 (1.9) 14 (8.5)
Autoimmune symptoms and disorders 1 (0.6) 1 (0.9) 1 (0.6) 2 (1.3) 1 (0.6)
Malignant neoplasms 1 (0.6) 1 (0.9) 2 (1.2) 1 (0.6) 2 (1.2)
*More than one AE or SAE could be reported in each patient; percentages represent the proportion of patients who reported >1 event.
AE, adverse event; MTX, methotrexate; SAE, serious adverse event.
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to septic shock following surgery. One patient who was
randomised to the placebo group died while receiving abatacept
between days 198–365 from pneumonia and sepsis. The
investigator assessment deemed the death possibly related to
study treatment.
Acute infusional events (7.1 vs 24.8%; table 3) were lower
with abatacept vs infliximab, respectively.
Up to day 365, infections and infestations were reported in
59.6 and 68.5% of the abatacept and infliximab groups,
respectively. Serious infections were reported in 1.9% of
abatacept-treated patients and 8.5% of infliximab-treated
patients (table 4). A total of five serious opportunistic infections
were reported, all occurring in the infliximab group in one
patient for each (encephalitis herpetic, lung infection pseudo-
monal, peritoneal TB, P jiroveci pneumonia and pulmonary TB).
Both cases of TB were in patients who were PPD test negative
and chest x ray negative at study entry. Between days 1–365,
autoimmune symptoms or disorders were uncommon (,1%)
and occurred at a similar frequency in the abatacept and
infliximab groups (table 2). No additional malignant neoplasms
were reported in either group between days 198–365.
DISCUSSION
The multi-centre, double-blind, placebo-controlled ATTEST
trial, examining the relative efficacy and safety of abatacept or
infliximab vs placebo, confirms that both biologics are effective
for the treatment of RA. Over the 12-month study, a relative
difference in safety was observed, with fewer SAEs, serious
infections, acute infusional events and discontinuations due to
AEs in the abatacept group than the infliximab group.
Following 6 months of treatment, abatacept and infliximab
on a background of MTX significantly reduced the signs and
symptoms of disease (DAS28 (ESR); ACR 20, 50 and 70), and
improved physical function (HAQ-DI) and quality of life (SF-
36) compared with placebo, in patients with an inadequate
response to MTX. The relative efficacy of abatacept and
infliximab at day 197 was similar, as the 95% CIs for the
Table 3 Frequently occurring acute infusional events (>2.0% of patients in any group) to day 197 and day 365
Acute infusional events
Days 1–197 Days 1–365
Abatacept + MTX
(n=156)
Placebo + MTX
(n=110)
Infliximab + MTX
(n=165)
Abatacept + MTX
(n=156)
Infliximab + MTX
(n=165)
n (%) n (%) n (%) n (%) n (%)
Total patients with AEs 8 (5.1) 11 (10.0) 30 (18.2) 11 (7.1) 41 (24.8)
Hypotension 0 0 7 (4.2) 0 8 (4.8)
Headache 2 (1.3) 2 (1.8) 7 (4.2) 2 (1.3) 7 (4.2)
Nausea 2 (1.3) 1 (0.9) 6 (3.6) 3 (1.9) 7 (4.2)
Flushing 1 (0.6) 0 4 (2.4) 1 (0.6) 5 (3.0)
Dyspnea 0 0 4 (2.4) 0 5 (3.0)
Urticaria 0 1 (0.9) 4 (2.4) 0 8 (4.8)
Pruritus 0 0 2 (1.2) 0 5 (3.0)
Dizziness 0 0 2 (1.2) 1 (0.6) 4 (2.4)
AE, adverse event; MTX, methotrexate.
Table 4 Serious infectious events to day 197 and day 365
Days 1–197 Days 1–365
Abatacept + MTX
(n=156)
Placebo + MTX
(n=110)
Inflixima + MTX
(n=165)
Abatacept + MTX
(n=156)
Infliximab + MTX
(n=165)
n (%) n (%) n (%) n (%) n (%)
Total patients with SAEs 8 (5.1) 13 (11.8) 19 (11.5) 15 (9.6) 30 (18.2)
Infections and infestations 2 (1.3) 3 (2.7) 7 (4.2) 3 (1.9) 14 (8.5)
Pneumonia 2 (1.3) 0 2 (1.2) 2 (1.3) 3 (1.8)
Sinusitis 1 (0.6) 0 0 1 (0.6) 0
Postoperative wound infection 0 1 (0.9) 0 0 1 (0.6)
Soft tissue abscess 0 1 (0.9) 0 0 0
Infective bursitis 0 1 (0.9) 0 0 0
Bronchitis 0 0 1 (0.6) 0 1 (0.6)
Cellulitis 0 0 1 (0.6) 0 1 (0.6)
Gastroenteritis 0 0 1 (0.6) 0 1 (0.6)
Herpes zoster 0 0 1 (0.6) 0 1 (0.6)
Lung infection pseudomonal 0 0 1 (0.6) 0 1 (0.6)
Pneumocystis jiroveci pneumonia 0 0 1 (0.6) 0 1 (0.6)
Infection skin ulcer 0 0 0 1 (0.6) 0
Encephalitis herpetic 0 0 0 0 1 (0.6)
Erysipelas 0 0 0 0 1 (0.6)
Lobar pneumonia 0 0 0 0 1 (0.6)
Peritoneal tuberculosis 0 0 0 0 1 (0.6)
Pulmonary tuberculosis 0 0 0 0 1 (0.6)
Septic shock 0 0 0 0 1 (0.6)
MTX, methotrexate; SAE, serious adverse event.
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rates, HAQ-DI responses and HRQoL improvements over-
lapped. However, by day 365, the 95% CIs for the treatment
difference between abatacept and infliximab for the reduction
in DAS28 (ESR), good EULAR responses, LDAS, the ACR 20
response rate and the HRQoL physical summary measure did
not include zero, suggesting a difference favouring abatacept for
these specific endpoints.
While the onset of response (as assessed by ACR 20
responses), initially appeared more rapid with infliximab,
similar response rates were noted with abatacept and infliximab
by day 85. Between 6 months and 1 year, abatacept responses
were maintained, while those with infliximab were not. The
sustained efficacy observed at 1 year compared with 6 months
in abatacept-treated patients is consistent with results from
other abatacept trials.
23 Similarly, the finding that patients
treated with infliximab did not sustain response rates over 1
year is also consistent with previous trials.
11 When the impact of
adding additional therapies was assessed using a sensitivity
analysis according to the last score prior to addition, reductions
in disease activity tended to be consistently higher with
abatacept than with infliximab.
Overall, abatacept had a relatively more acceptable safety and
tolerability profile than infliximab. Over 1 year, fewer SAEs,
AEs, infections, and discontinuations due to AEs or SAEs were
observed with abatacept relative to infliximab. Generally,
opportunistic infections appeared to be relatively uncommon
in this study and were mainly observed in the infliximab group,
including two events of TB, an event of P jiroveci pneumonia, an
event of pseudomonal lung infection and an event of herpes
encephalitis. No opportunistic infections were reported in the
abatacept group. Autoimmune symptoms or disorders were
uncommon (,1%) with abatacept and infliximab. All of the
malignancies were reported during the first 6 months, including
one in the abatacept group, one in the placebo group and two in
the infliximab group.
The data presented here should be interpreted within the
context of several limitations. Although collectively the data
support a relatively more acceptable risk-to-benefit profile of
abatacept compared with infliximab, the design of this study
utilised the infliximab dose of 3 mg/kg, without dose adjust-
ment. At the time of the study, the recommended dose of
infliximab (approved labelled starting dose for RA) was 3 mg/
kg; however, today regulatory agencies recognise the use of
higher doses of infliximab, and physicians use them in a
proportion of patients to maintain a durable response. In fact,
the dose may be increased in up to 30% of patients.
12 Although
higher doses have been associated with an increased risk of AEs
in clinical trials.
51 3 Finally, this study was not designed to
evaluate the effect of abatacept or infliximab vs placebo on
radiographic progression.
In conclusion, these two biologic therapies with two distinct
mechanisms of action have different safety and efficacy profiles;
however, abatacept and infliximab both offer clinical improve-
ments to patients with an inadequate response to MTX. Over 1
year, abatacept exhibited a durable response, and had a
relatively more acceptable safety and tolerability profile than
infliximab, as evidenced by fewer SAEs, serious infections, acute
infusional events and discontinuations due to AEs.
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